Journal
CURRENT OPINION IN GENETICS & DEVELOPMENT
Volume 19, Issue 1, Pages 44-50Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.gde.2008.12.003
Keywords
-
Categories
Funding
- Novartis Pharmaceuticals, Inc.
- National Cancer Institute [CA89393, CA94074]
- Department of Defense [W81XWH-04-1-0452]
Ask authors/readers for more resources
Cancer stem cells and their potential roles in tumor heterogeneity are currently subjects of intense investigation. Studies suggest that these cells may develop from any normal cell and have begun to elucidate their molecular profiles. The percentage of a tumor composed of cancer stem cells varies greatly, and researchers believe that multiple types of these cells may exist in a single neoplasm. Cancer stem cells may be formed by epithelial-mesenchymal transition and seem to be less prevalent in metastases than in corresponding primary tumors. These cells appear to have therapeutic sensitivities different from those of cancer cells with more differentiated features. Looking into the many questions that remain about the cancer stem cells model might lead to more effective cancer prevention, diagnosis, and treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available